Aarti Pharmalabs Limited — Updates, 16-04-2025: Press Release

Aarti Pharmalabs Limited has achieved a significant sustainability milestone with the approval of its Greenhouse Gas (GHG) emission reduction targets by the Science Based Targets initiative (SBTi). This recognition makes it the sixth Indian pharmaceutical/CDMO to secure comprehensive approval covering all three emissions scopes since its 2022 demerger. The company's commitment entails reducing Scope 1 and 2 emissions by 37.8% by FY2030 and achieving net-zero emissions across its entire value chain by FY2050.

This achievement is expected to enhance Aarti Pharmalabs' market position, appealing to sustainability-focused partners and supporting compliance with evolving environmental standards. Strategic initiatives will include adopting low-carbon technologies and optimizing operational efficiency to meet ambitious targets. The effort underscores Aarti’s dedication to a greener future, potentially contributing to long-term value creation for stakeholders.